Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of resectable hepatocellular carcinoma with portal vein tumor thrombus.
Signed written informed consent and able to comply with scheduled visits and rel... [+15]
PVTT located in the portal vein branch opposite the tumor, or with inferior vena... [+20]